Navigation Links
Karmanos Physician-Scientists Examine Racial Disparities in,Patients with Gynecologic Cancer

DETROIT, April 16, 2007 /PRNewswire/ -- Karmanos Cancer Institute physician-scientists today reported on two research studies investigating racial disparities in patients with gynecologic cancer at the American Association of Cancer Research annual meeting in Los Angeles, CA.

Caucasian patients with endometrial or ovarian cancer, on average, live longer than their African American counterparts. Led by Veronica Schimp, D.O., assistant professor of gynecologic oncology, Karmanos Cancer Institute, Wayne State University, two studies were conducted to determine if this stems from the molecular composition of the tumor, or the aggressiveness of the treatment plan. Dr. Schimp's presentation, Outcomes of Endometrial and Ovarian Cancer Treatment and Ethnicity, was part of the conference's Minorities in Cancer Research Forum.

Endometrial Cancer Patients - Racial Disparities at the Molecular Level?

Dr. Schimp's team analyzed the molecular profiles of endometrial cancer in a group of 150 Caucasian and African American patients using a number of known molecular markers. The tumors' expression of these markers was compared based on ethnicity and tumor type (Type I = endometrioid carcinomas, hormone-related tumors and Type II = non-endometrioid carcinomas, non-hormone related tumors which are more clinically aggressive).

"Upon conclusion of the five-year study, we found the molecular profiles were similar between the two ethnic groups," explains Dr. Schimp. "While African American patients with endometrial cancer seemed to show a trend toward a shorter survival, this seemed to be mainly due to their higher proportion of Type II tumors which are more aggressive by nature."

Ovarian Cancer Patients - Racial Disparities Based on Treatment Plan?

Karmanos researchers conducted a study to determine whether the survival rates among African Americans with ovarian cancer are shorter than those of Caucasians due to a less aggressive treatment plan. These treatment plans may be prescribed by the physician, chosen by the patient, or due to a lack of treatment options.

Over seven years, Karmanos physician-scientists followed a group of 170 Caucasian and African American ovarian cancer patients through similar treatment plans, consisting of surgery and chemotherapy. The study revealed, out of the 70 percent of patients who had optimal tumor reduction surgery followed by chemotherapy, the Caucasian patients lived 16-20 months longer than the African American patients.

These results were compared to the Charlson co-morbidity index, which predicts the one-year mortality for a patient who may have a range of co-morbid conditions, such as a patient suffering from cancer along with diabetes.

"African Americans were found to have higher co-morbidity scores, meaning they may have additional factors that contribute to their cancer survivability rate," said Dr. Schimp. "Our study revealed that, in part, a patient's outcome is based on her co-morbidity score, not only on the biology of her cancer or aggressiveness of the cancer treatment."

Based in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer. The Institute is one of 39 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D. is the Institute's president and CEO.

Barbara Ann Karmanos Cancer Institute

CONTACT: Courtne y McCrimmon, +1-412-225-6899, or Linda Remington,+1-313-576-8614, both of Barbara Ann Karmanos Cancer Institute

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
2. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
6. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
7. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
8. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
9. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
10. Data Presented at the American Academy of Neurologys Annual Meeting Provide Update on Utilization and Safety of Tysabri in Patients with Multiple Sclerosis
11. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... With Thanksgiving right around the corner, holiday travel season ... protect your family and vehicle. , According to the National Highway Traffic Safety Administration, ... is sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... it has been designated an Aetna Institute of Quality® Bariatric Surgery Facility for ... the quality and cost of health care services available to its members to ...
(Date:11/24/2015)... M.D. (PRWEB) , ... November 24, 2015 , ... ... new award for its exceptional customer service: the TrustDale certification. The award recognizes ... The Baltimore stone honing , tile and grout, and hard surface restoration ...
(Date:11/24/2015)... ... , ... Autism Speaks, the world’s leading autism science and advocacy organization, will ... generosity of people around the world. On December 1, supporters can make an online ... share the personal stories behind those gifts. , Just as Black Friday and ...
(Date:11/24/2015)... ... ... All her life, Don Peck’s mother wondered if she was a descendant of Samuel Fuller, ... After a 25-year search for information, Don and his aunt discovered that she was not, ... Turns out, it was Don’s father who was descended from not one, but four passengers ...
Breaking Medicine News(10 mins):